Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Doug Hutcheon, MD

    TitleClinical Assistant Professor of Medicine (Clinician Educator)
    SchoolKeck School of Medicine of USC
    DepartmentMedicine
    AddressIRD 2020 Zonal Ave.
    Off Campus
    Los Angeles California 90033

       Overview 
       Overview
      Dr. Hutcheon's major areas of research interest are the diagnosis and treatment of acute and chronic venous thromboembolism with a special interest in hypercoaguable states, and incorporating evidence-based medicine into quality improvement and cost-conscious decision making in internal medicine residency training. Dr. Hutcheon is also passionate about teaching residents how to initiate effective end-of-life and goals-of-care discussions.

      Dr. Hutcheon earned his medical degree from Case Western Reserve University School of Medicine. He then went on to complete his internship and residency from University of Pittsburgh Medical Center on the Internal Medicine-Clinical Scientist Track.


       Biography 
       Awards and Honors
      Occidental College1998 - 2002Presidential Scholarship
      Occidental College Department of Chemistry2001Analytical Chemistry Award
      Case Western Reserve University2007 - 2011Dean's Scholarship

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007 Aug 1; 110(3):556-63..
        View in: PubMed
      2. Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T, Morris C, Small EJ. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs. 2007 Oct; 25(5):445-51..
        View in: PubMed
      Back to TOP